MedTrace Logo

Evaluation of Brain Neurotransmitter Levels in Adults With ADHD, Before and After Stimulant Treatment

NCT04823364 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-07-15

No results posted yet for this study

Summary

Background:

Attention deficit hyperactivity disorder (ADHD) is one of the most prevalent neurobiological brain disorders. Diagnosis of ADHD in adults is complex and subjective. Recent studies give further support for the involvement of glutamatergic and GABAergic neurotransmitters in the pathophysiology of ADHD. Studies show that glutamate (Glu) and GABA change according to stimulant treatment. Measuring modulations in the anterior cingulate cortex (ACC) of Glu and GABA may help to explore the pathophysiology of ADHD and give a diagnostic biomarker tool for ADHD in adults.

Aim:

To characterize Glu and GABA levels in the ACC, by using the proton Magnetic Resonance Spectroscopy (\[1H\]MRS) system in adults with ADHD compared to healthy control subjects (HCS), before and after stimulant treatment, and to correlate between Glu and GABA levels and clinical symptoms.

Method:

ADHD adults ages 18-40 years (N= 35), and HCS (N= 25), will fill out a DSMV and ASRS questionnaire.

Spectroscopic analyses will be done using 1H MRS (3T) in ADHD adults, before and after stimulant treatment (Methylphenidate /Mixed Amphetamine salts) in an open-label fashion as compared to HCS. Proton spectra will be acquired from the ACC.

Conditions

  • Attention Deficit Disorder With Hyperactivity

Interventions

OTHER

Neurotransmitters evaluation by MRS

Baseline MRS screening for volunteers and ADHD groups and repeated measurement for ADHD group after taking stimulant drug treatment

Sponsors & Collaborators

  • Tel Aviv University

    collaborator OTHER

  • Maccabi Healthcare Services, Israel

    collaborator OTHER

  • Weizmann Institute of Science

    lead OTHER

Principal Investigators

  • Assaf Tal, PhD. · Maccabi Healthcare Services, Israel

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-07-11
Primary Completion
2024-07-11
Completion
2024-07-11

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04823364 on ClinicalTrials.gov